Chemodex

Oridonin

CHF 48.00
In stock
CDX-O0131-M0055 mgCHF 48.00
CDX-O0131-M02525 mgCHF 162.00
More Information
Product Details
Synonyms 7α,20-Epoxy-1α,6β,7,14-tetrahydroxy-Kaur-16-en-15-one, NSC 250682
Product Type Chemical
Properties
Formula

C20H28O6

MW 364.43
CAS 28957-04-2
RTECS NZ8177000
Source/Host Chemicals Plant
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO (20mg/ml), DMF (20mg/ml) or ethanol (20mg/ml). Insoluble in water.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key SDHTXBWLVGWJFT-XKCURVIJSA-N
Smiles O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@@](C4=O)([C@@H]5O)[C@@]2([H])CC[C@H]5C4=C)([H])C(C)(C)CC1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Oridonin is a diterpenoid that has been found in R. rubescens and has anti-inflammatory and anticancer, antimicrobial and neuroprotective properties. The regulatory anticancer mechanisms include induction of apoptosis and autophagy, inhibition of proliferation, inhibition of angiogenesis, cell cycle arrest. It is an inhibitor of the TLR4/p38-MAPK and TLR4/NF-κ signaling pathways and PPARγ. Oridonin is a high affinity inhibitor of NLRP3 inflammasome assembly and activation (Kd = 52.5 nM). It inhibits inflammation in wild-type, but not Nlrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes. Also inhibits glial activation, decreases inflammatory cytokine release, attenuates synaptic loss and improves behavioural deficits in Aβ1-42 treated mice. CRL/SCF RING E3 inhibitor. Inhibits Fbw7 an E3 ubiquitin ligase (CRL/SCF RING) of c-Myc and promotes proteasomal degradation.

Product References

(1) T. Ikezoe, et al.; Int. J. Oncol. 23, 1187 (2003) | (2) J.J. Liu, et al.; Ann. Hematol. 83, 691 (2004) | (3) T. Ikezoe, et al.; Mol. Cancer Ther. 4, 578 (2005) | (4) Q. Cui, et al.; J. Pharmacol. Sci. 105, 317 (2007) | (5) H. Wang, et al.; Oncol. Rep. 24, 647 (2010) | (6) H.L. Huang, et al.; Mol. Cancer Ther. 11, 1155 (2012) | (7) Z. Liu, et al.; Cell Prolif. 45, 499 (2012) (Review) | (8) S. Wang, et al.; PLoS One 9, e104745 (2014) | (9) B.A. Owona & H.J. Schluesener; Drugs R.D. 15, 233 (2015) (Review) | (10) S. Wang, et al; PLoS One 11, e0151397 (2016) | (11) L. Tian, et al.; BMC Complement. Altern. Med. 17, 192 (2017) | (12) J. Li, et al.; Int. Immunopharmacol. 55, 9 (2018) | (13) J. Xu, et al.; Molecules 23, E474 (2018) (Review) | (14) H. He, et al.; Nat. Commun. 9, 2550 (2018) | (15) T. Jia, et al.; Int. Immunopharmacol. 69, 382 (2019)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.